Heart failure (HF) is a clinical syndrome with signs and symptoms that result from any
structural or functional deterioration of ventricular filling or ejection of blood. It is the final …

Background Sacubitril/valsartan has been highly efficacious in randomized clinical trials of
patients with HFrEF. However, the effectiveness of sacubitril/valsartan in routine US clinical …

Background: The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to
enalapril in patients with reduced ejection fraction (HFrEF). Since its publication, several …

Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at
high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is …

One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …

Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited
exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high …

Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at
high risk of morbidity and mortality. Sacubitril valsartan (previously known as LCZ696) is a …

Introduction Sacubitril/valsartan has demonstrated improvement in survival in patients with
heart failure (HF) and reduced ejection fraction. However, the population studied in the …

Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has
become a milestone in the treatment of patients with chronic heart failure (HF) with reduced …

Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral
blood flow. The development of natriuretic peptide (NP) through inhibition of the neprilysin …